NCT05478603View on ClinicalTrials.gov

A Study to Understand How the Study Medicine (PF-07081532) is Processed in People With Liver Dysfunction

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

April 5, 2023

Study Completion Date

April 5, 2023

Conditions
Hepatic ImpairmentHealthy Volunteers
Interventions
DRUG

PF-07081532

PF-07081532 20 milligrams (mg), 1 tablet orally, once on Day 1

Trial Locations (2)

32809

Orlando Clinical Research Center, Orlando

33603

Genesis Clinical Research, LLC, Tampa

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY